Bcl-2 protein is chosen by FRMT as an important marker in the COAD dataset; This finding broadly supports the work of Poincloux et al., linking loss of Bcl-2 protein expression with increase in relapse of stage II colon cancer, and it could be a potential histo-prognostic marker in therapy decision making [82]. Here, BCL2 is linked to colonic neoplasm.